Ontology highlight
ABSTRACT:
PROVIDER: PRJNA482961 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The ascidia Halocynthia roretzi (Phylum: Chordata, Subphylum: Tunicata, Class: Ascidiacea) have been used as model species in development biology for over a century. It offers attractive experimental features, including a compact genome, invariant embryonic cell lineages, small embryonic cell number, and translucent embryos, which allow the description of developmental processes with a cellular level of resolution. Staged RNA-seq data has been already deposited in DDBJ (accessiton number DRA005714 and DRA005711). In the present study, we sequenced genome of H. roretzi of a southwestern Japanese population using RNA-Seq data. These RNA-Seq data covers expressions in 8 cell and 110 cell embryos of Animal(A), Vegetal(V) and whole-embryo regions. These genome assembly, transcript assembly, and transcript models are incorporated into the ANISEED (https://www.aniseed.cnrs.fr/) for genome browsing and blast searches. The genome and transcriptome resources will be useful datasets for developmental biology, evolutionary biology and molecular ecology using this model organism.
2024-03-16 | GSE195613 | GEO
Project description:Halocynthia roretzi strain:Type C Genome sequencing and assembly
| PRJNA481447 | ENA
Project description:Dynamics of gene expression across the embryonic development of Halocynthia roretzi
| PRJNA418107 | ENA
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
| 2533916 | ecrin-mdr-crc